Publication details
Farmakogenetické testy a jejich současné využití v psychiatrické praxi
| Title in English | Pharmacogenetic testing and its current use in psychiatric practice |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | psychiatrie |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.cspsychiatr.cz/dwnld/CSP_2022_6_237_239.pdf |
| Keywords | pharmacogenetic testing; CYP 450 2D6; precision psychiary; treatment optimisation |
| Description | Aim: The aim of this study was to evaluate the use of pharmacogenetic testing in patients with psychiatric diagnosis. Method: Since 1997, genotyping and phenotyping of CYP2D6 has been available at the Brno-Bohunice University Hospital and paid for by the insurance company. Results. Most of the examinations were performed in the first decade in the framework of clinical trials focused on the influence of CYP2D6 activity on the efficacy and tolerance of antidepressant treatment. The number of requests has steadily declined over time. Discussion: possible reasons are discussed, including the lack of correlation with available plasma level determinations. Conclusion: Determination of the genotype and/or phenotypes of the most important enzymes metabolizing psychopharmaceuticals will facilitate and expedite the choice of the next treatment strategy in the non-responding individual. Pharmacogenetic testing of drug-metabolizing enzymes together with therapeutic drug monitoring (TDM) should be available at least in university hospitals where difficult-to-treat patients accumulate. |